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Sulphonamide Chemotherapy was first introduced 
into therapeutics by Colebrook and Kenny in 1956 
working on the problem of the treatment of puerperal 
infections. Their work was based on the observations 
of Domagk in 1955. He found that experimental mice 
were protected against lethal doses of haemolytic 
streptococci by the administration of prontosil, a 
compound of sulphanilamide. The power of the
sulphanilamide to inhibit the growth of the invading 
streptococci was shown to be dependent on some way on 
the living organism. It has been suggested that the 
drug alters the bacteria in such a way as to favour 
natural phagocytosis.but the exact mode of action is 
still uncertain.
Colebrook (1936) treating cases of puerperal 
infection at Queen Charlotte's Hospital, London, 
demonstrated that prontosil was capable of producing 
dramatic improvement and reduction of mortality in 
patients infected with haemolytic streptococci of the 
highly virulent type A. It was immediately recognised 
that this discovery would have considerable significance 
in the treatment of the numerous diseases due to
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streptococcal infection and particularly the commoner 
ones such as scarlet fever and erysipelas.
Success with streptococcal Infections naturally 
suggested trials of the new drug in other infections.
Whitby (1937) was able to show that sulphanilamide 
besides being effective against streptococci, was also 
similarly active against, meningococci, gonococci and 
bacillus coli.
At the same time other sulphonamides were introduced 
in an attempt to find a specific remedy for infections 
with organisms such as staphlococci and pneumococci.
In 1938, Whitby announced a new Sulphonamide, viz.
2 ()d: aminobenzenesulphonamido) pyridine, commonly known 
as M.& B.693. with bacteriostatic powers over pneumococci 
equal to the action of sulphanilamide over streptococci. 
Moreover the new drug was just as effective against 
streptococci, meningococci and gonococci.
Such discoveries naturally stimulated interest in 
the treatment of the common diseases known to be caused 
by those organisms and sulphonamides came to be used in 
Streptococcal infections of all kinds, Gonococcal 
infections, Meningococcal Meningitis, Pyelitis and 
Cystitis due to B.coli infection and the Pneumonias.
Some of those diseases have a high mortality rate and 
the frequency with which all of them occur in the 
practice of medicine, made this innovation in treatment
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a matter of first rate importance.
New therapeutic agents must necessarily be used 
with caution till their dangers and their value are 
established. The production of those new chemical 
compounds, however, has been so rapid that it has been 
difficult to assess their limitations, their contra­
indications and their clinical worth by proper extensive 
trials. The potential danger of this state of affairs 
is apparent•
Before new treatments supercede the old, they must 
show an improvement in results and prove themselves to 
be at least as safe and convenient in application as 
the old.
This new treatment is of especial interest in the 
work of an infectious diseases hospital. Moreover in 
such an hospital it is usually possible to obtain a 
series of patients, suffering from the commoner infections, 
sufficiently large to give significant results in the 
evaluation of methods of treatment.
Since 1935 I have been in charge of Thornton 
Isolation Hospital - an hospital of about 80 beds 
serving the populous south-west district of the County 
of Fife. During the past three years therefore, I have 
had the opportunity of studying the effects of sulphon- 
amides on a large number of patients under constant 
conditions in hospital, besides using the drug in 
suitable cases occurring in my private practice.
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The Sulphonamides which I have used in those 
investigations are:-
1. Sulphanilamide.
This in the great majority of cases was
as Streptocide (Evans) and in the others,
as Prontosil Album (Bayer).
2. Compounds of Sulphanilamide.
1. Prontosil Red. (Bayer)
2.a.Proseptasine.')(May & Baker) 
b.Soluseptasine.j Benzyl derivatives of
sulphanilamide.
5. Uleron (Bayer) 
b. M.& B.693. or 2(b.aminobenzenesulphonamido) pyridine.
I propose to give an account of the clinical 
experience gained in the use of those new drugs, and 
also, a summary of the results obtained from their 
exhibition in the treatment of streptococcal infections, 
(particularly Scarlet Fever and Erysipelas),urinary 
infection with Coliform bacilli, meningococcal 
meningitis, gonorrhoeal ophthalmia neonatorum, para­
typhoid carriers and pneumonia.
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Streptococcal Infections.
When Sulphanilamide was shown to act as a 
specific remedy for puerperal infections with 
haemolytic streptococci, it was immediately put 
on trial in the treatment of diseases in which 
the haemolytic streptococcus was known to be the 
causal agent. Scarlet fever, which is numerically 
the predominating disease in most infectious diseases 
hospital^, and which is always caused by infection 
with haemolytic streptococci, offered the most 
promising field for treatment with the new drug.
Other diseases due to haemolytic streptococcal 
infection, not so common as scarlet fever, but 
none the less important on account of their severity, 
such as Erysipelas and Streptococcal empyema were 
reasonably expected to be within the scope of the 
new treatment.
For the past three years therefore, sulphanilamide 
or one of its compounds have been used in the treatment 
of scarlet fever, erysipelas and streptococcal empyema. 
As will be discussed later, it was also used in the 
treatment of puerperal infections, many of which 
were probably due to streptococcal invasion.
1. Scarlet Fever.
It is now generally accepted that Scarlet Fever 
is always due to an infection of some part of the body -
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usually the fauces - with Streptococci^which may 
conform to any one of the twenty-eight different 
types of haemolytic streptococcus pathogenic to 
man. (Banks 1939).
Clinically the severity of Individual cases of 
scarlet fever varies within very wide limits.
In a rural area such as is served by Thornton 
Isolation Hospital, scarlet fever tends to occur in 
Small local epidemics. Each epidemic produces cases, 
which are similar in severity, which have the same 
features in the initial stage of the disease and which 
tend to develop the same complications. Thus, cases 
from one village may have the faucial Inflammation as 
the most salient feature, whereas cases from another 
area may have a profuse rash and mild throat symptoms; 
in one epidemic, there may be a noticable tendency to 
otitis media as a complication and in another an increase 
in the rate of renal complications. Those observed 
clinical facts corroborate the bacteriological evidence 
that scarlet fever may be produced by different types 
of haemolytic streptococci, if the reasonable assumption 
is made that each type has different predilections in 
its attack on the body.
It is therefore impossible to assess the value of
any particular treatment, except in a large series of
0
cases. Moreover the only certain method of getting 
reliable results is by selecting every second patient
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for the therapeutic trial and using the others as 
controls.
In the great majority of cases, Scarlet fever 
is not a dangerous disease and the mortality rate is . 
low. Complications however are common and cause a 
good deal of disability and ill health.
The assessment of the value of any treatment 
therefore cannot be based on the mortality rate but 
must be made on (a) the relief afforded during the 
acute stage and on (b) the reduction of the incidence 
of complications.
About the beginning of 1937, I began to treat 
Scarlet fever patients with Sulphanilamide. At first 
the sulphanilamide was used cautiously and patients to 
be treated with it were selected in a haphazard way.
After a few months, when it was seen that the drug 
could be safely used in all ages without severe toxic 
symptoms, alternate patients were given the sulphanilamide 
from the time of admission to hospital. This was 
continued till July 1939.
Throughout this test period, the preparation of 
sulphanilamide used was Streptocide (Evans). This was 
given by mouth in tablets each containing £ gram or ^ 
gram of Sulphanilamide.
The daily dose of sulphanilamide varied according 
to the age of the patient; £ gm. was given to children
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up to five years of age, 1-| gms. were given to school 
children and 3 gms* to older patients per day. This 
amount was given in three equal doses. When a patient 
was admitted in an acutely ill condition the first dose 
was doubled.
The full daily amount of the sulphanilamide was 
continued till the temperature became normal - thereafter 
it was reduced by a third of the daily amount each day 
for three days.
With recurrence of the fever the sulphanilamide 
was recommenced and administered as at the onset.
In this manner 224 patients suffering from Scarlet 
Fever were treated with Sulphanilamide.
For control purposes, I have records of a series 
of 338 patients suffering from Scarlet Fever treated in 
hospital over the same period of time and in exactly 
the same manner apart from the fact that no sulphanilamide 
was given. The period of time occupied by the control 
series overlaps that of the test series both before m d  
afte,r.
A few of the severe cases in both groups were 
given anti-streptococcal serum on admi»sion.
all cases in which the diagnosis was in doubt 
have boen excluded from both series.
The cases under review occurred in several minor
in
epidemics of varying severity and/one major epidemic
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during the winter 1937 to 1938 when the disease met 
with was more than usually severe, besides those 
occurring in the usual sporadic form.
Patients suffering from Scarlet Fever are very 
rarely admitted to hospital before the appearance of 
the rash has made the diagnosis clear. Hospital 
treatment therefore is seldom instituted before the 
second day of illness.
In both the control and the test series I found 
that 90# of the patients were admitted within the first 
72 hours of the onset of the illness. Also, in each 
series, all but 5# of the patients had an elevated 
temperature on admission to hospital.
Those factors being constant, the number of days 
from the onset of the illness till the patient became 
afebrile is a convenient and moderately reliable standard 
of comparison of the severity of the initial acute phase 
of the disease in the two series.
The cases In each series were therefore grouped 
according to the day of Illness on which the temperature 
returned to normal and remained normal. The percentage 
number in the group for each day in each series is given 
in the following table for convenience in comparison.
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Day of illness on which temperature became normal.
1. 2 3 4 5 6 7 8 9
TO &
over
Patient 3 trea ;ed wi1th Sul ohanile mide.
5.8# 2.7# 3.6#- 3.6 # 11.6# 22.3# 28.5# 16.1# 4.9#
Control Serie s.
24.8# 11.5# 5.4# 2.9# 2.1# 2.1#- 5.3# 19.5# 23.9#
As will be readily seen from the table, there Is 
no evidence that the sulphanilamide hastened the fall 
of temperature in the acute stage of the disease.
Those figures corroborate the clinical findings 
during the experiment. It appeared to me then, that 
the patients treated with sulphanilamide did not improve 
any more quickly than the untreated cases. The drug 
had no obvious effect on acutely ill, toxic patients, 
and the temperature often remained at a high level 
even after three days treatment. In one instance, 
a child of l£ years suffering from malignant scarlet 
fever, following a burn on the arm, died 24 hours 
after admission, although she was given both sulph­
anilamide and anti-scarlatinal serum. This was the 
only fatal case during the period reviewed and is not 
included in the series.
The chief danger of scarlet fever is undoubtedly 
in the risk of complications. Any investigation of 
the value of methods of treatment must therefore depend 
largely on an examination of the late results of
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treatment and the Incidence of the various complications.
A summary of the complications occurring in the
patients in each series has been made. Those are
grouped in the following categories, and the number in
each expressed as a percentage of the number of patients
in the series.
1. Ear, Throat & Nose complications.
This group includes otitis media, discharging 
ears, rhinitis and persistent septic conditions 
of tonsils.
2• Cervical Adenitis.
The cervical glands are practically always swollen 
and tender during the acute stage. This primary 
adenitis was disregarded. The patients included 
in this group all had secondary swellings of the 
cervical glands, usually in the second or third 
week of illness, and almost always it was attended 
by elevation of temperature. In a certain number 
in each series, the swelling went on to abscess 
formation, but those cases have not been separated.
3. Nephritis.
Cases of all grades of severity from albuminuria 
to haemorrhagic nephritis are grouped together.
Cases of transient albuminuria during the initial 
febrile illness are not included.
4. Heart complications.
The criterion for inclusion in this group has been 
tachycardia, Irregularity of the heart's action, 
cardiac murmurs or enlargement sufficient to warrant 
the patient being kept in bed longer than usual, on 
this account.
5. Rheumatism.
This has always been In the form of joint pains 
with or without swelling^and elevation of temperature,
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The results are set forth in the following table:
Type of 
Complication
Ear,Throat 
& Nose
Complications
Cervical
Adenitis
"Nephritis Heart
Com-
pli-
ca-
tioni.
Rheu­
ma­
tism.
Series
treated with 
Sulphanila­
mide
11.5# 12.5# 2.5# 9# 3#
Control 
Series. 7.5# 11.5# 2# 5.5# .6#
Examination of the table shows at once that the 
incidence of complications in the patients treated with 
Sulphanilamide was actually greater than in the control 
series.
This again is in accordance with the impression 
formed in the wards during the test period.
The slightly greater frequency of complications in 
the patients treated with sulphanilamide might suggest, 
that the drug had a harmful effect on the course of the 
disease. The difference is too small, in my opinion, to 
be conclusive regarding this point, though the question 
of tbxioity of the drug as a possible cause of the 
increase in complications cannot be disregarded entirely.
Throughout the experiment some of the patients 
treated with sulphanilamide showed evidence of mild 
toxic reactions to the drug, but, in no case was there 
symptoms of a serious nature.
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The most frequent toxic sign was cyanosis, 
noticable as a dusky blue colour of the lips and 
finger tips. This did not inconvenience the patient 
in any way and did not appear to be dangerous. It was 
usually regarded as a caution signal and in one or two 
instances the drug was stopped more quickly than usual 
on this account. The cyanosis disappeared in 24 hours 
or so after the drug was stopped.
Nausea was a fairly common reaction to the drug 
but vomiting was rare.
A few patients developed urticarial, or macular 
rashes on the limbs and trunk. Those skin eruptions 
faded rapidly when the drug was stopoed.
Throughout the experiment, patients, while having 
sulphanilamide were given no saline aperients, and no 
food or medicine rich In sulphur. This precaution 
certainly reduces the risk of toxic reactions, particularly 
the risk of cyanosis.
Young children appear to tolerate the drug rather 
better than adults.
On the whole, I think the toxic symptoms were not 
sufficiently serious or of sufficient gravity to cause 
the increase in the incidence of complications in the 
patients treated with Sulohanilamide.
The Manufacturers of the drug issued a warning that 
there might be a risk of the sulphanilamide causing renal 
damage in some cases. It will be noted from the table
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that the difference between the treated and untreated 
patients as regards renal damage is insignificant, 
showing that the drug had apparently no deleterious 
effects on the kidney.
Some of the patients with late ccmplications of 
scarlet fever, such as otitis media, rhinitis and 
glandular abscesses were treated with sulphanilamide 
orally. I have not a sufficiently large number to 
draw definite conclusions and it is extremely difficult 
to get any idea of the value of a particular treatment 
when the disease process is so variable. My impression, 
however, is that Sulphanilamide is of no value whatever 
in the cervical adenitis and of doubtful value in otitis 
media and rhinitis.
In otitis mediayart rhinitis and in septic skin 
conditions secondary to them, direct application of the 
sulphanilamide in the form of ointment or drops has been 
tried with successful results.
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2. Erysipelas.
Since 1936 I have treated 54 patients suffering 
from erysipelas with sulphanilamide and compounds of 
sulphdnilamide. Owing to the lack of material it was 
not possible to have another series of patients to act 
as controls•
The disease met with was extremely variable both 
as regards the site and the extent of the inflammation.
There were no deaths in the series but this is of 
little significance in a disease which is rarely fatal 
except in very young or debilitated patients.
The success of any treatment of erysipelss must 
be judged by the effect on the fever and toxaemia caused 
by the disease and by the arrest of the spread of the 
inflammatory process in the skin.
In this small series, which included patients of 
all ages, those criteria were so varied that a numerical 
statement of results would be without value.
I shall therefore give only an account of my 
clinical impressions formed during the course of treat­
ment.
At first Prontosil Red (Bayer) was the preparation 
used. Adults were given 10 c.c. to 30 c.c. per day, 
intramuscularly, depending on the severity of the
disease. Children were given ^ to  ^of this amount.
(Evans)
Later sulphanilamide as Streptocide/was given by mouth
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ln doses of f gm. to 3 gms. per day depending on the 
age of the patient and the severity of the disease.
In some cases, treatment was instituted by an intra­
muscular injection and then continued by oral administra­
tion. Proseptasine and Soluseptasine (both made by 
May & Baker) were used in some cases in a similar manner.
All of the patients in the series showed an im­
provement within 24 to 48 hours of the commencement of 
the treatment with the sulphanilamide preparation.
This was evidenced by a fall in temperature, a lessening 
of the toxaemia and a subsidence of the erysipelatous 
inflammation.
As far as could be ascertained there was no 
difference in the results with the different compounds 
of sulphanilamide and the pure sulphanilamide.
Oral administration was found to be just as
effective as intramuscular injection. In some cases
give
the drug given by mouth appeared to/better results than
by the intramuscular route.
It was found that it was necessary to continue the
treatment for a few days after the patient had become
afebrile, in order to avoid recurrence of the disease.
Two instances of the efficacy of this chemotherapy
In erysipelas are given for illustration.
Case 1. A child of two months was admitted to hospital 
on 14/2/37 in her fourth day of illness.
On admission the temperature was 103.6°P, and 
there was erysipelas involving the right ear, right
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cheek, right occipital region and across the nape 
of the neck.
On the 5th day of illness the inflammation had 
spread across both cheeks and the temperature was 
105*P. 5 c.c. Prontosil were given at mid-day and 
the temperature gradually fell during the ensuing 
24 hours.
On the 6th day of illness, the inflammation was 
still spreading, the general condition was deteriorating 
and in the afternoon the temperature which had fallen 
almost to normal, again rose to 105.4°F. A second 
5 c.c. of Prontosil was given intramuscularly and f gm. 
of Proseptasine was given by mouth in three doses.
On the morning of the 7th day of illness the 
temperature had fallen to 99 P and the general 
condition was improved although during the night 
there had been further spread of the inflammation 
involving both arms and both forearms and most of 
the back. 1-| gms. of Proseptasine was given in 
three doses throughout the day. The temperature 
fell to normal.
On the 8th day of illness the inflammation was 
subsiding and the child was very well otherwise.
On the 15th day the patient was discharged from 
hospital, well.
-■•a 1
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A copy of the temperature chart of this case 
is given.
The only alarming feature of the case was the 
temporary brignt pink colour of the baby following 
the injections of Prontosil.
This case is quoted because erysipelas in such 
a young subject has always been regarded as having a 
grave prognosis.
Case 11.
In February 1937, a lady aged 70 years of age 
with chronic nephritis, high blood pressure and 
failing heart developed a patch of erysipelas on 
her nose. This was observed at 10 a.m. as a red 
spot and by 10 p.m. of the same day the whole nose 
was fiery red and the patient's temperature was 
elevated. She was immediately given hm. of 
sulphanilamide by mouth and this was continued 
i gm. three times the following day. Within 
24 hours the inflammation was subsided and the 
sulphanilamide was stopped. The erysipelas with 
elevated temperature reappeared M b* two days later 
and again subsided following administration of 
sulphanilamide. The drug was continued for several 
days without recurrence of the inflammation.
Although the kidney function was seriously 
impaired there was no evidence of immediate or 
late toxic effects of the drug.
The preparation in this instance was Prontosil 
Album (Bayer).
A noticable feature in this series of cases was 
that although the ordinary erysipelatous inflammation 
subsided quickly following sulphanilamide administration, 
localised pockets of inflammation were not so amenable 
to this treatment.
The following case illustrates this clinical fact.
An infant, 3 weeks old, was admitted to hospital 
on 14/3/38 with severe erysipelas over the whole 
abdomen apparently originating from the umbilicus. ,
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12-| c.c. of Prontosil w«re given Intramuscularly 
in five doses during the first 24 hours in hospital 
and 2% c.c. per day thereafter for the following 
3 days.
By 17/3/38 the disease was arrested and all 
inflammation had subsided excepting an abscess 
formation in the umbilicus.
On 18/3/38 the Prontosil was stopped but on 22/3/38 
the erysipelas had recurred and the temperature was 
again elevated. The erysipelas had again spread 
from the -umbilicus. Daily doses of 2-g c.c. Prontosil 
intramuscularly were recommenced and the erysipelas 
again cleared rapidly leaving only a hard indurated 
area round the umbilicus. The prontosil was again 
stopped on 27/3/38, although there was still a hard 
mass deep to the umbilicus.
On 29/3/38 with a sharp rise of temperature the 
umbilicus began to discharge pus freely. There 
was no recurrence of the erysipelas and the whole 
condition cleared up rapidly.
On 9/4/38 the child was discharged from hospital 
well with the umbilicus completely healed.
Similar experiences with other cases of erysipelas 
having abscess formations prior to the administration 
of sulphanilamide, corroborate the fact that sulphanilamide 
chemotherapy is effective against the diffuse inflammation 
of erysipelas only, and is not active in curing an in­
flammatory process which has become walled off as in the 
formation of an abscess.
All the patients with erysipelas while being treated 
with sulphanilamide etc. were having a light diet con­
taining no foods known to be rich in sulphur. Saline 
and sulphur laxatives were avoided. In no case was 
there evidence of serious toxic symptoms.
Cyanosis and nausea occurred occasionally but were 
never sufficient to disturb the patient to any extent or
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to require discontinuance of the drug. 
j. Streptococcal Empyema.
During 1937 three patients suffering from 
streptococcal empyema were treated with sulphanilamide 
preparations; two were treated with sulphanilamide 
given as Streptocide (Evans) and one with Proseptasine 
(benzyl sulphanilamide) M.& B.
In two of the cases the empyema developed following 
influenzal pneumonia and in the other it resulted from 
a puerperal infection.
Case 1.
iPman, 30 years of age, was admitted to hospital 
in January 1937, suffering fran influenzal pneumonia. 
Ten days later he developed empyema. Aspiration 
gave a thin purulent fluid containing streptococcus 
haemolyticus in pure culture. He was given f gram 
of proseptasine per day, and his temperature, pulse 
and respirations returned to normal. Nevertheless 
thick pus collected in the pleural cavity and I found 
it necessary to resect a piece of rib to establish 
free drainage. He made an uneventful recovery 
following his operation.
Case 11.
A man, aged 26 years, was admitted to hospital 
on 26/0/37 with influenzal pneumonia of 10 days 
duration. On admission he was in extreme distress 
with dyspnoea and cyanosis. Temperature 103®F.
Pulse rate 130 p.min. and respirations 58 p.min.
There were obvious signs of fluid in the right 
pleural cavity and on aspiration 18 ounces of thin 
purulent fluid were withdrawn.
Culture of the fluid was reported as giving a pure 
growth of streptococcus haemolyticus.
\ gm. of sulphanilamide was given four hourly, 
fluid from the
Aspiration of the/pleural cavity was repeated on 
28/3/37 and 2/4/37 - 2 ounces of thin pus being 
withdrawn on each occasion.
-21-
Clinical signs continued to indicate improvement 
and at the next aspiration on 10/4/37 no fluid could 
be obtained. His general condition improved gradually 
and his temperature, pulse rate and respirations were 
normal from 20/4/37.
Exploration of the chest on 1/5/37 gave no fluid.
He was discharged fit on 17/5/37.
His streptococcal empyema was thus cleared with 
aspiration of pleural fluid on three occasions only 
and without recourse to surgical drainage.
Case 111.
In June 1937, a woman, aged 30 years was admitted 
to hospital with puerperal infection. Besides the 
puerperal parametritis she was found to have fluid 
in the left pleural cavity. Aspiration gave thin 
pus which was reported to give a pure streptococcal 
growth on culture.
She was given ^ gm. of sulphanilamide four hourly.
Her chest was aspirated on five occasions and the 
pus never became thick.
Her chest cleared completely - it was possible to 
verify the result in this case by X Ray - without 
any need for rib resection.
Those three cases suggest that sulphanilamide is 
of value in the treatment of streptococcal empyema and 
that, if given early enough and in sufficient dosage, it 
will be possible for the pleural fluid to be cleared by 
aspiration alone.
The failure of the proseptasine to prevent thick 
pus formation may have been due to insufficient dosage 
in the early stage of the empyema or it may have been 
due to the different composition of the drug. The 
drug appeared to improve the condition of the patient 
by lessening toxaemia. Thus he was afebrile while
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taking the drug in spite of the collection of thick 
pus in the pleural cavity.
Prom this experience it is certainly justifiable 
to treat cases of Streptococcal empyema with sulphan­
ilamide in large doses while the pleural fluid is being 
aspirated. Some cases will probably be cured by 
aspiration without giving the drug, but, I think 
simultaneous administration of sulphanilamide will 
tend to make less frequent, the necessity for subsequent 
operation.
4. Puerperal Infections.
During the past two years 40 patients suffering 
from puerperal sepsis have been treated in Thornton 
Isolation Hospital, and Prontosil or Sulphanilamide 
has been used in every case.
Puerperal sepsis may be caused by infection with 
any one of several different organisms, though it is 
recognised that a high percentage of the serious cases 
are due to infection with haemolytic streptococcus.
Owing to the lack of convenient laboratory 
facilities at Thornton it has not been possible to make 
a bacteriological grouping of the patients in the series. 
For this reason any attempt to analyse the results of 
treatment would be valueless.
I shall therefore give only a general statement 
of my clinical findings.
From my experience, I have reason to believe that
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sulphan11amide therapy is a valuable aid in treating 
puerperal infections. In one or two cases who were 
desperately ill the course of the disease appeared to 
be dramatically checked by the drug.
The action of the drug was not constant, however, 
Several patients died or had protracted febrile illnesses 
in spite of large doses of prontosil intramuscularly 
and sulphanilamide orally.
Toxic signs, viz. cyanosis, nausea and sickness 
were much more readily induced in puerperal cases then 
in cases of erysipelas or scarlet fever. This may be 
accounted for by the more or less profound anaemia 
present in most of the puerperal patients.
One or two patients developed extensive macular 
and morbilliform eruptions on the skin, due apparently 
to the sulphanilamide.
No permanent toxic effects were noted.
It has become the practice in the hospital to treat 
all puerperal infections with sulphanilamide.
This course appears to me to be justifiable, when 
some severe cases are greatly improved by the drug and 
when no serious harm is done to those cases which do not 
respond to the sulphanilamide.
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From the foregoing observations it will be seen 
that Sulphanilamide has not a uniform action in diseases 
due to Streptococcal infections. Erysipelas is cured 
by the drug, while Scarlet Fever is uninfluenced, 
though both diseases are due to infection with the 
haemolytic streptococcus. The explanation of this 
anomaly is probably that Scarlet Fever is due to the 
toxins elaborated by the streptococcus in s localised 
focus, whereas, Erysipelas is due in large measure to 
a widespread invasion of the tissues by the streptococci. 
Thus streptococcal antitoxin is a more effective remedy 
in Scarlet Fever than in Erysipelas.
I have shown the inefficacy of sulphanilamide in 
the cases with abscess formation in the course of 
erysipelas.
I think it is reasonable therefore to assume that 
sulphanilamide is only an effective remedy in those 
cases of streptococcal infection in which the organisms 
are easily accessible to the drug via the blood or tissue 
fluids.
Thus streptococcal empyema in the early fluid stages 
and puerperal blood stream infections should be expected 
to be amenable to sulphanilamide therapy.
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Collform Bacillus infection of the urinary tract.
10 patients suffering from pyelitis were treated 
with sulphanilamide. Most of the cases occurred as 
pyelitis complicating pregnancy. In all the cases 
coliform bacilli were present in abundance in the 
urine, and the illness was acute, with pain, high fever 
and frequency of micturition.
In each instance the usual alkaline treatment had 
failed to give a permanent cure.
The dose given was \ gm. of sulphanilamide three 
times per day.
Within 48 hours of the commencement of treatment 
there was an improvement in the general condition of 
the patient and a disappearance of symptoms in every 
case. This was confirmed in each instance by a dis­
appearance of the coliform bacilli from the urine, as 
observed microscopically. The rapid change in the 
microscopical findings in the urine was in fact even 
more impressive than the clinical improvement.
It was observed however that the treatment in no 
way lessened the tendency of the disease to relapse.
My impression is that sulphanilamide,in relatively
small doses^is a very useful drug in the treatment of
pyelitis and cystitis due to infection with coliform
bacilli. Though it obviously does not offer a per-
the
manent cure for the disease it rapidly clears/symptoms 
and signs of the acute phase of the illness. Moreover 
it can be conveniently combined with the usual alkaline
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treatment of the disease.
In this series of cases an incident occurred 
which emphasises the need for strict supervision of 
patients treated with sulphanilamide.
A woman, aged 25 years, suffering from pyelitis 
of pregnancy was being treated at home with gm. of 
sulphanilamide three times per day. She had been 
warned to take no saline or sulphur laxatives but 
nevertheless she took a large dose of compound liquorice 
powder. The following day she became deeply cysnosed, 
her lips, mucous membranes and finger nails being deep 
purple in colour. Apart from the cyanosis she was not 
seriously ill and when the drug was stopped she recovered 
her normal colour in a few days. At this time she was 
eight months pregnant. There were no adverse effects 
on the pregnancy which terminated successfully three 
weeks later.
Provided the usual precautions are taken, sulphanila­
mide in the above dosage, is in my experience, as 
effective and less toxic than Mandelic acid in the 
treatment of urinary infections with coliform bacilli.
Meningococcal Meningitis.
Pour patients suffering from meningococcal 
meningitis have been treated with sulphonamide drugs 
during the past 2 years.
Meningococcal antitoxin (Parke Davis & Co) 
intrathecally and intravenously has given good results
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in former years in the treatment of meningitis and 
it was thought to be inadvisable to discontinue this 
method of treatment entirely.
All the cases were treated with completely successful 
results.
During the two years prior to the introduction 
of prontosil only two cases of meningococcal meningitis 
were dealt with a Thornton Isolation Hospital. One 
case during 19o5 made a good recovery and one case 
during 1936 died.
I shall give details of the four cases treated 
with sulphonamides.
Case 1.
Arthur Fowler aged 17 years was admitted to 
hospital on 5/3/37 in his eighth day of illness.
On admission he was semi-conscious with nuchal 
rigidity and squint.
Lumbar Puncture. Cerebro spinal fluid was purulent 
and under High pressure. 19 c.c. were allowed to 
run off. Meningococcal antitoxin 15 c.c. were 
given intrathecally. 20 c.c. prontosil red was
given intramuscularly.
As soon as he was able to swallow he was to have 
i- gm. sulphanilamide three times per day.
Meningococci were found in the cerebro spinal fluid.
On 6/3/37 he was much improved, both mentally and 
physically. Squint had disappeared.
He was given Meningococcal Antitoxin 15 c.c. 
intravenously and the sulphanilamide by mouth was 
continued. On 7/3/37 his temperature was normal 
and remained so thereafter. General condition 
much improved.
Lumbar puncture - 18 c.c. turbid fluid ran off and 
he was given Meningococcal antitoxin 5.c.c. intra­
thecally and 22 c.c. intravenously.
On 8/3/37 - Improving - given 3 .c.c. meningococcal 
antitoxin intravenously.
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On 10/3/37 Lumbar puncture gave 15 c.c. of clear 
fluid under slight pressure. Sulphanilamide was 
stopped. Meningococcal antitoxin 5 c.c. intrathecally 
and 1 0  c.c. intramuscularly given.
On 12/3/37 Lumbar puncture showed cerebro spinal fluid 
clear. He was given meningococcal antitoxin 4 c.c. 
intrathecally and 8  c.c. intravenously.
On 16/3/37 Lumbar puncture. Cerebro spinal fluid clear 
and pressure normal.
On 26/o/37 Lumbar puncture. Cerebro spinal fluid clear 
and pressure normal. Cells 2 p.cram.
On 2/4/37 he was discharged fit.
He had a total of 7 gms. of sulphanilamide, 20 c.c. 
of prontosil red and 1 0 2  c.c. of meningococcal antitoxin 
by various routes.
Case 11.
Wm.Brown, aged 14 years, was admitted to hospital 
on 12/1/38 at 10 a.m. in his third day of illness. He 
was unconscious on admission and extremely restless.
On admission lumbar puncture had to be done under 
general anaesthesia.
Cerebro spinal fluid was purulent, 32 c.c.run off 
under high pressure. He was given meningococcal anti­
toxin 15 c.c. Intrathecally, 10 c.c. intravenously and 
5 c.c. intramuscularly.
Soluseptasine 5 c.c. was given Intramuscularly.
At 8.30 p.m. on same day lumbar puncture was again done 
under general anaesthesia. 1 0  c.c. turbid fluid taken 
off. He was then given meningococcal antitoxin 15 c.c. 
intravenously and 15 c.c. intramuscularly. Soluseptasine 
5 c.c. was given intramuscularly. Morphia was given 
to quieten him at night.
15/1/38. He was conscious and without eye symptoms, 
although there was severe headache and nuchal rigidity. 
Meningococcal antitoxin was given , 10 c.c. intravenously 
and 3 c.c. intramuscularly. Sulphanilamide £ gm. four 
hourly by mouth.
14/1/38. He was much improved. Lumbar puncture now
possible under local anaesthesia. Cerebro spinal fluid
now much clearer, 28 c.c. taken off under slight 
pressure.
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Meningococcal antitoxin 9 c.c. given intravenously.
15/1/38. Improving. Lumbar puncture.25 c.c. cerebro 
spinal fluid under pressure but much clearer. Meningo­
coccal antitoxin 1 0  c.c. given intramuscularly.
16/1/38. Improving. Lumbar puncture. 20 c.c. clear 
cerebro spinal fluid non off. Meningococcal antitoxin 
1 2  c.c. given intramuscularly.
18/1/58. Now very well. Lumbar puncture. 12 c.c. clear 
cerebro spinal fluid run off.
1/2/28. Allowed up and sulphanilamide by mouth stopped. 
9/2/38. Discharged fit.
Total amount of sulphanilamide given was about 28 gms.
1 0  c.c. of soluseptasine given during the first day and 
in all 104 c.c. of meningococcus antitoxin was given 
by various routes.
Case 111.
George Dickson, aged 17 years, was admitted to 
hospital on 16/o/39 in his fourth day of illness.
On admission he had definite meningeal irritation 
with double vision. He was drowsy but could co-operate 
in the examination.
Lumbar puncture (under local anaesthesia) 45 c.c. 
purulent cerebro-spinal fluid under high pressure were 
taken off. He was given meningococcal antitoxin 13 c.c. 
intrathecally and 17 c.c. intravenously. 2 gms. of 
M.& B.693 was given by mouth as an initial dose 
followed by 1 gm. 2 hourly.
17/5/59. Much improved but restless.
lumbar puncture. 45 c.c. pdrulent cerebro■spinal fluid 
taken off. Meningococcal antitoxin 14 c.c. intrathecally 
and 16 c.c. intravenously given.
18/3/39. Lumbar puncture. 25 c.c. less turbid cerebro- 
spinal fluid run off. Meningococcal antitoxin 14 c.c. 
intrathecally and 16 c.c. intravenously given.
The M.& B.693 was reduced to 1 gm. 4 hourly.
19/5/59. General condition improved.
Lumbar puncture. 30 c.c. rather less turbid cerebro- 
spinal riuld run off. Meningococcal antitoxin 15 c.c.given 
intra muscularly.
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20/3/39. Much improved.
Lumbar puncture. 30 c.c. cerebro* spinal fluid run off. 
Less turbid. 15 c.c. meningococcal antitoxin intra­
muscularly.
22/3/59. Lumbar puncture.40 c.c. cerebro spinal fluid 
taken off” Fluid now almost clear.
24/5/59. Now very well generally.
Lumbar puncture. 35 c.c. cerebro spinal fluid, clear 
but under pressure.
27/3/o9. Lumbar puncture. 30 c.c. clear cerebro-spinal 
fluid taken off. Pressure still above normal.
7/4/39. Cerebro-spinal fluid clear and cells normal.
15/4/39. Discharged cured.
A total of 48 gms. of M.& B.693 was given by mouth, 
no sulphanilamide preparation given by injection end 
1 2 0  c.c.of meningococcal antitoxin given by various 
routes.
This boy’s temperature was normal from the eighth 
day of illness.
Case IV.
Kathleen McNaughton aged 2 years was admitted to 
hospital on 3/2/39 in her third week of illness.
There was a history of her having stiffness of 
neck and weakness of one arm for 2 weeks. Her 
mother had a simjntaneous illness proven to be due 
to meningococcal infection.
On admission there was definite nuchal rigidity. 
Lumbar puncture. 30 c.c. slightly turbid fluid taken 
off under pressure.
This fluid was reported to have the picture of 
meningococcal meningitis though the organism was not 
found.
M.&B.693 i gm. by mouth 4 hourly.
4/2/39. Meningococcal antitoxin 20 c.c. given 
intramuscularly.
5/2/39. Nuchal rigidity still present.
Lumoar puncture. Pressure still increased.
1 0  c . c .  meningococcal antitoxin given intrathecally and 
2 0  c.c. intramus cularly.
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6/2/59. No nuchal rigidity.
7/2/59. Lumbar puncture. Pressure of cerebro spinal 
fluid still above normal.
9/2/59. Lumbar puncture. Pressure of cerebro spinal 
fluid normal.
20/2/39. M.& B.693 stopped.
4/3/59. Discharged well.
Total amount of M.& B.693 given was about 16 gms. 
spread over two weeks. There was no sulphonamide 
given by injection. 50 c.c. of meningococcal anti­
toxin were given in all.
This, the only case from which the meningococcttS 
was not recovered was of the chronic type. The con­
comitant meningococcal meningitis in the mother (treated 
in JPerth) and the clinical signs in the child were 
taken as sufficient evidence to include the case in 
this series of meningococcal meningitis.
Definite conclusions cannot be based on such a 
small series of cases. The complete recovery and the 
rapid amelioration of symptoms and signs in a disease 
of such gravity suggest that the sulphonamide preparations 
were of some value in the treatment. On theoretical 
grounds the combination of the antitoxin with a 
bacteriacidal drug appears to be the ideal treatment.
In order to establish the value of the drug 
it would be necessary to omit the antitoxin therapy 
in a few cases, but, from my experience with suloh- 
anilamide in scarlet fever, I am very reluctant to 
do so, in such a highly dangerous disease as meningococcal 
meningitis.
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Staphlococcal Infection.
Uleron, a German sulphonamide, was introduced early
in 1938 by Bayer Products Ltd.. with the claim that it
against staphlococci 
had a bacteriocidal action/in the body. The chemical
denomination of this drug is (4 -(4 amino-benzol-sulphonamido) 
-benzol-sulphon-dimethyl-amide).
My experience with this preparation is limited to 
one case only. This is reported here because this 
patient, suffering from staphlococcal pyaemia presented 
an excellent opportunity for a clinical trial of the 
drug.
Mitchell (1938) reported success with the drug 
in the treatment of five cases of acute osteomyelitis 
due to Staphlococcus aureus.
I am unable to confirm his good report on the 
action of the drug.
In August 1937 a man aged 45 years, developed a 
staphlococcal blood infection following a severe septic 
finger. He was treated with sulphanilamide % gm. four 
hourly for a week without any improvement in his con­
dition or lessening of the infection.
During the ensuing months he developed abscesses 
in both arms, in his shoulder, in the lumbar region of 
the back, in the legs, over the occipital region of the 
head, and in the left eye. The eye infection resulted 
in panophthalmitis necessitating enucleation of the 
eye-ball.
-o^-
In May 1958 the pyaemia was still present and 
fresh abscesses were developing in the bones of the 
legs, arms and skull.
He was now treated with Uleron. He was given a 
series of short courses of treatment with two or three 
days between each, as recommended by the manufacturers. 
The object of this was to avoid toxic symptoms. Each 
course consisted of 2 gms. of Uleron per day in four 
doses for 3 or 4 days. In this manner he was given 
six courses.
No improvement whatever could be recorded and he 
actually developed fresh abscesses while under treatment 
with the drug.
The pus from the abscesses was reported to give 
pure growths of staphlococcus aureus on culture.
It would appear therefore that in this case the 
Uleron was not capable of killing staphlococcus aureus 
in the blood stream during the course of the pyaemic 
process.
This patient is still uncured (August 19o9) .
During the course of the treatment of this patient 
with Uleron I formed the opinion that it was a more toxic 
drug than sulphanilamide. This particular case at least 
tolerated the sulphanilamide much better than the Uleron.
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Ophthalmla Neonatorum.
During the year 1938 fifteen babies with 
ophthalmia neonatorum were treated with sulphonamide 
drugs in addition to the standard treatment of Irrigation 
and silver drops. In the first eight months of the 
year sulphanilamide (streptocide) was used; thereafter 
the new sulphonamide, M.& B.693 was the preparation 
used. The daily dose of both sulphanilamide and 
M.& B.693 was \ gm. given in three equal quantities.
The babies tolerated the drugrwell, there being no 
appreciable toxic effects either with the sulphanilamide 
or the M.& B.693.
Only five of the cases were proved to be due to 
gonococcal infection of the eyes. The other ten cases 
were reported to have pneumococci or diphtheroid organisms 
in the purulent discharge from the eyes.
The gonococcal cases all occurred in the early part 
of the year and were treated with sulphanilamide.
Every case recovered completely without permanent 
damage to the eyes•
Similar results however have been obtained in 
previous years.
The time taken for the eyes to become free from pus 
in those few cases, was not sufficiently reduced from the 
time taken in cases treated in previous years, to say 
whether the sulphanilamide influenced the course of 
the disease or not.
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In May 1939 a severe case of gonococcal 
oohthalmia neonatorum was treated with M.& B.693.
The unusually rapid effect of treatment in this 
instance suggests that the M.& B.693 contributed 
largely to the cure of the disease.
A female child born on 7/5/39 was admitted to 
hospital on 10/5/39 with a history of discharge from 
both eyes since the day of birth.
On admission, weight was 7f- lbs. There was 
profuse, thick, yellow, purulent discharge from both 
eyes. The eyelids of both eyes were red and oedematous. 
Both corneae were hazy.
The baby was admitted in the afternoon and during 
the same evening was given two doses of M.& B.693, each 
-£*gm. The eyes were instilled with lunosol drops once 
that day and irrigated with boric lotion two hourly.
During the night the eyes were severely inflamed 
and were discharging profusely.
At 6 a.m. the following morning both eyes were 
noted to improve markedly and from this time the 
discharge was very scanty and watery in type, although 
the eyelids were still red and swollen. The M.& B.693 
was continued gm. t.i.d.
On the morning of the 14/5/39 both eyes were 
completely free from inflammation and discharge. On 
the same evening the baby had some cyanosis and the 
M.& B.693 was discontinued. The total quantity given was
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2igms•
The baby was discharged, cured, on the morning 
of 18/5/39.
Thornton Isolation Hospital has been the centre 
for treatment of all cases of ophthalmia neonatorum 
occurring in the County of Fife for the past ten years. 
In the hospital It has never been known for a proven 
gonococcal ophthalmia to be free from purulent discharge 
within 24 hours of admission to hospital.
This case would indicate that M.& B.693. is the 
most valuable treatment for gonococcal ophthalmia yet 
tried, and certainly superior in this respect to 
sulphanilamide.
This drug will certainly be the sulphonamide of 
choice in the treatment of gonococcal Infections of 
the eyes.
Para-typhoid Fever.
Three patients convalescent from enteric fever, 
due to infection with B.paratyphosus B., were found 
to be in the carrier state. The usual remedies had 
failed to clear the faeces of pathogenic organisms.
In each case sulphanilamide, 1? gm. every four 
hours, was given for a week and the faeces again 
examined. B.paratyphosus B. was recovered from the 
faeces in each instance.
One of those patients had also been treated with
- 5 7 -
sulphanilamlde during the acute stage of the disease, 
without effect on the fever or the toxaemia.
Those cases are included because it has recently 
been reported that sulphanilamide may be of value in 
the carrier state of enteric fever (Cookson 19o9)
Pneumonia.
In July 1938 Evans and Gaisford reported notable 
success in the treatment of pneumonia with the latest 
sulphonamide, 2-(p-Aminobenzenesulphonamido)-pyridine 
or M.& B.693. Their work was the sequel to Whitby's 
discovery that in ’in vivo’ experiments with mice,
M.& B. 693 had a lethal effect on pneumococcal cultures.
At Thornton Isolation Hospital from 60 to 90 
patients suffering from pneumonia are treated annually. 
Those patients, I find, are removed to hospital mainly 
for two reasons, viz.(l.) In the course of the illness 
the patient has become critically ill#pr, (2 ) the 
patient’s home is too poor to provide sufficient 
accommodation and material for proper nursing.
The patients admitted to hospital then are usually 
acutely ill and many of them are suffering from defective 
nutrition.
Those factors combine to produce a heavy mortality 
in patients suffering from pneumonia, met with In 
hospital practice.
During the past few years the mortality figures
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for patients of all ages suffering from all types of
pneumonia have been:-
During 1935, - 65 cases treated with a mortality of 14$
" 1936, - 87 " ” " " " " 24$
M 1937, - 84 " " " " " " 13$
During first 7 months of 1938, 73 cases treated
with a mortality of - 19$
Those figures are closely similar to mortality 
rates found among hospital patients suffering from 
pneumonia in various parts of the Country. Thus Evans 
& Gaisford quote the rate at Sellyflak Hospital,Birmingham 
as 25.6$, that at Middlesex and Royal Free Hospitals, 
London, as 19$ and that at Dudley Road Hospital for 
the past two years as 27.8$
In private practice and in healthy individuals there 
is no doubt that the mortality rate is much lower. In 
Osier & McCrae's textbook on the Practice of Medicine 
6 $ is quoted as the mortality rate in a large series 
of private patients. It is also quoted that in 
40,000 cases of pneumonia in the German Army the death 
rate was 3.6$.
It is of course generally recognised that the 
mortality rate in pneumonia varies more with the age 
than with any other single factor. Thus at the Royal 
Hospital for Sick Children, Glasgow, the mortality r'-te 
varied from 65$ in infants under 6 months to 3$ in 
children between the ages of 10 and 14 years (L.Findlay 
in Thomson's Sick Children) and over the age of 60 years
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the mortality may be as high as 80$ (Beaumont & Young 
in Price's Textbook of Medicine).
Another extremely important factor bearing directly 
on the mortality rate in pneumonia is the type of 
pneumococcus with which the patient has become infected.
The patients being treated at Thornton Isolation
Hospital are of all ages from the very young to the
the
very old, though the great majority of/patients are 
children or young adults.
So far it has not been possible to carry out any 
investigation of the incidence of the various types of 
pneumococci in the cases of pneumonia treated.
In August 190 8 , I decided to use the new drug 
M.& B.693 in the treatment of pneumonia. At first, 
my intention was to treat only every second case with 
the M.& B.693. in order to have a concurrent series 
of cases for controls. This scheme was abandoned, 
however, in a very short time. The treated cases were 
noted to improve so rapidly, that it was felt to be wrong 
to withhold the treatment in control cases which were 
desperately ill. For example, in three children 
(nos. 60, 62 & 6 6 in the series) aged 13 months, 2 years 
and 2£ years, all ill with broncho-pneumonia, the M.& B 
693. was withheld for 6 days, 3 days and 6 deys, res­
pectively, during which time they had high fever and 
were acutely ill. In each case when the course appeared 
to be becoming unfavourable M.& B.693 was given and
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wit hin 24 hours the temperature was normal and the 
toxaemia abated.
Experiences such as those make it difficult to 
keep rigorously to scientific methods when dealing 
with a highly fatal disease such as pneumonia.
It was therefore decided to treat every case 
admitted with pneumonia with M.& B.693.
During the past year there were 66 cases of 
pneumonia treated in hospital with M.& B.693.
This series included patients of all ages from 
3 months to 70 years. There were 24 patients of 
2 years of age and under, there were 28 patients 
between the ages of 2 years and 30 years, and there 
were 14 patients over 30 years of age.
34 of the patients had pneumonia of the lobar 
type and 32 had broncho pneumonia or lobular pneumonia.
In the descriptive list of patients given below, the 
patients are grouped according to the type of pneumonia. 
This however is of little importance because it is often 
extremely difficult to be certain clinically which tyre 
of pathological process is taking place in the lung.
All of the patients in the series were suffering 
from pneumonia with definite signs and symptoms. Patients 
who were notified and admitted as pneumonia and later 
found to be suffering from bronchitis, influenza, 
tuberculosis etc. were not included in the series, 
though in many cases they also were treated with M.& B.693.
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By this selection, there were no fatal or unsuccessful 
cases excluded from the series.
The routine fresh air treatment was continued as 
in former years. Prior to August 1938 I gave three 
daily doses of a mixed pneumococcal, streptococcal snd 
influenzal vaccine to patients admitted within 48 hours 
of the onset of illness. This was discontinued in the 
present series of patients.
X Ray examination was not used in diagnosis as 
this is impracticable at Thornton Isolation Hospital.
No bacteriological investigation^ of the cases 
was done, i.e. neither examination of the sputum nor 
typing of the infecting pneumococci. This would 
undoubtedly have been desirable. There are no 
laboratory facilities within 20 miles of the hospital 
however and the exigencies of general practice made it 
impossible for time to be spent in typing pneumococci 
at the bedside.
The dosage of the M.& B. 693 which was adopted in 
this series, was based on the recommendations of Evans 
& Gaisford. It was modified in individual cases 
according to my previous experience with sulphanilamide.
An adult was given 2 gms. on admission followed 
by 1 gm. every four hours for two days. Thereafter 
if the reaction was favourable, the dose was reduced to 
\ gm. four hourly and gradually reduced further with 
clinical improvement. In no case was the drug stopped
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till a few days after the patient became afebrile.
The dose was halved in cases of children of the 
school age and quartered for younger children.
In every case the drug was given by mouth. The 
total quantity given to each patient depended on the 
severity of the disease, the tolerance of the individual 
to the drug and the response to treatment.
There were 5 deaths in the 66 cases of pneumonia 
treated with M. & B.693, giving a mortality rate of 
7.6#.
The following table gives the mortality in the
three age groups.
Age Group 
of Patients
2 years & 
under.
From 2 years 
to 30 years.
Over
30 years
To'taT «TI
ages.
No.of
patients in 
each group 24 28 14 66
Mortality 
rate in 
each group 8# nil. 21# 7.6#
Details of the five fatal cases ere as follows.-
1. A frail,old lady of 70 years, Her pneumonia was 
of the hypostatic type and she was afebrile from 
the time of admission. She died three days after 
admission.
2. A child of 4 months, admitted on the 9th day of 
illness with broncho pneumonia. She was given % gm. 
of M.& B.693,4 hourly. She gradually became worse and 
36 hours after admission developed convulsions and 
died an hour or so later.
3. A marasmic child of 6 months admitted on the fourth 
day of illness with broncho pneumonia. He was given
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■| gm. M.& B. 693 on admission and \ gr,. four 
hourly thereafter. Re died three days after admission. 
The temperature was in the region of 101°F - 104*F. 
throughout and there was apparently no response to 
the drug.
4. A man, 50 years of age, admitted to hospital on his 
7th day of illness with broncho pneumonia at both 
bases. He was given 1 gm. of M.& B.693 four hourly.
He was delirious and extremely restless from the 
time of admission. Morphia was required as he could 
not be kept in bed. He gradually became worse and 
died 24 hours after admission, having had 5 gms. of 
M.& B.693.
5. A man of 60 years admitted on his 4th day of illness 
with pneumonia of the lobar type. At the end of 24 
hours during which time he had 5 gms. of M.& B.693 
his temperature was normal but his pulse rate had 
increased. He had a heavy cloud of albumin in his 
urine. He gradually became weaker and died 60 hours 
after admission.
Post mortem examination was not carried out in any 
of the fatal cases.
The comparatively low mortality rate of 7.6# gives 
the most concrete result of the administration of M.& B. 
693 to cases of pneumonia.
Early in the course of the experiment, however, 
after a few acutely ill patients had been treated, there 
was very little doubt in my mind as to the value of the 
drug. In the great majority of cases 36 to 48 hours 
of treatment was sufficient to produce a dramatic 
improvement in the condition of the patient somewhat 
resembling the crisis in the ordinary course of lob*r 
pneumonia, This occurred, however, irrespective of the 
stage of the disease and not, as usually occurs,always 
about the 7th day of illness. Thus in 48 patients in 
the series defervescence occurred within 48 hours after
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treatment with M.& B.693 was instituted. In the 34 
typical lobar cases 29 patients responded to treatment 
within 48 hours in this way.
The first indication of a favourable result was
usually a lessening of the t o x a e m i a . T h e  fall in
temperature and pulse rate and the improvement in
physical signs were usually more gradual than is seen
case
at the crisis in a typical/of lobar pneumonia. The 
pulse rate and the respiratory rate improved more 
slowly than the temperature, and frequently took one 
or two days to return to normal after the patient had 
become afebrile. This lag in the fall of the pulse 
and respiratory rates is explained clinically by the 
fact that the lung consolidation was noted to take 
several days to clear following the first improvement 
in the patient. In one or two cases, treated early, 
a gradual improvement of symptoms simultaneous with 
an increase in the consolidation of the lung was observed 
during the first few days. This anomaly seemed to 
indicate that although the pneumococcal growth and 
therefore the toxaemia had been checked, the pathological 
changes in the lung continued in their usual sequence 
viz. congestion, consolidation and resolution.
This is a matter of great importance I think in 
the conduct of the case. While the lung is still solid 
and the pulse rate higher than normal it is essential 
to restrain the patient from exerting himself unduly.
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This may be a real difficulty in a patient who has not 
been ill long enough to be in the extremely weak state 
seen subsequent to the ordinary crisis in lobar 
pneumonia and who has been given complete relief from 
severe symptoms. In hospital practice it is easy to 
ensure that sufficient rest is enforced but this is not 
always so in private practice when the patient is not 
being attended by competent nurses.
This danger was illustrated by Case No.4. a boy, 
strong and healthy, 21 years of age. He was the only 
patient treated at home in the series described.
On his 2nd day of illness when treatment was 
commenced he had severe pleurisy at the right base with 
temperature 103*P., cough,and blood stained sputum.
There was impaired percussion at right bsse, friction 
sounds and diminished air entry.
On the ord day he was much improved but there was 
now definite consolidation of the lung at the right base.
On the 4th day the temperature was normal and 
remained so.
The consolidation persisted till the 6th day when 
he was feeling so well that he got out of bed.
About the 10th day he complained of pain in the 
right lower chest again and signs of fluid were now 
present. He had no elevation of temperature and he 
felt very well otherwise.
About 5 c.c. of straw coloured fluid were aspirated
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and the chest cleared spontaneously with rest in 
ten days time.
In my opinion the boy’s pleural effusion resulted 
from excessive exercise before sufficient time had been 
given to allow resolution to take place.
The danger of such a condition is of course 
simultaneous infection of the fluid with organisms 
and the possibility of the development of empyema.
In the following tables the patients are grouped 
according to the type of pneumonia from which they 
suffered. Thus No's 1 to o4 were all more or less 
typical cases of lobar pneumonia: No's 55 to 66 were
of the bronchopneumonic type.
The patients are also grouped according to the 
day of illness on which treatment with M.& B.693 was 
instituted. The frequency with which the drug produced 
rapid improvement and fall in temperature is thus 
clearly seen.
Patients with Lobar Pneumonia.
Wo. Day treat­
ment began
1st day 
afebrile
Age Total
M&B 693
Results.
1. 2nd day 4th 52 25 gms. Cured.
2. n 3rd 19 8 " n
3. n 4th 28 18 " fi 1
4. ii 4th 21 10 " Pleural effusion. Aspirated 
Spontaneous absorption.
5. 3rd day 4th si 8 gms.
Apical pneumonia. Acutely 
ill on admission. Cured.
6 . n 4th 3 8 " Apical pneumonia. Acutely 
ill on admission. Cured.
7. i 7th 21 23 " Extremely ill on edmission. 
Dense dullness right b^se. 
Cured.
8 . i 4th 34 16 " Cured.
9. ti 8th si 16-g " Cured.
1 0 . 4th Day 6th 11 11 " Cured.
11. n 5th 12 6 " Cured.
12. ii 5th 6 0 5 " Temp.fell in 24 hours. Pulse 
rate increased. Died 60 
hours after admission.
13. n 5th 6 6 " Cured.
14. it 6th 2 f 7i " Cured.
15. ti 6th 17 isi " Cured.
16. ii 6th 44 25£ " Cured.
17. ii 5th 5 11 " Cured.
18. n 6th 26 25^ " Cured.
19. n 5th 7 6i " Cured.
2 0 .
ii 6th 16i 1 gm. 
t .i.d.
Temp.rose on 8th day pnd in 
spite of M&B.693 she had 
irregular temp.and spreading 
pneumonia for 4 weeks. Finrl 
cure by lysis.
21 . n 15ctms. Cured.
22. n 5th 11 6 i  " Cured.
No. £>ay treat­
ment began.
1st day 
afebrile.
Age Total 
M&B 693
Results.
23. 5th 10th 5 i gm. 
t.i.d.
This was an early case in 
the series & I do not 
think had a big enough 
dose. Cured.
24. it 6th 11 9 gins. Cured.
25. n 6th 17 14 " Cured.
26. n 7th 17 29 " Acutely ill & delirious 
on admission. Delirium 
clear in 12 hrs. Cured .
27. ii 6th 65 12 " Cured.
28. n 6th 39 62 n Chronic bronchitis also. 
Relapse on 8th day & temp, 
did not fall then till 
16th day. Cured.
29 6 th 7th 54 14£ " Cured. [;
30. n 7th 14 5| "
- - - -  j
Cured. j
ol. i i 7 th 4 5 " Cured.
32. i i 7 th 41 17 " Cured.
33. 7th 9th 10 i o £  " Cured.
34. ti 11th 23 21 " Cured.
Patients with Broncho Pneumonia. 1
35. 2nd afebrile 70
4 hrlyl
Died. Hypostatic 
oneumonia.
36. ii 4th 2 5 gms. Cured.
37. i i 3rd 1 3f " Cured.
38. 3rd 5th 1* 5 "
Suffering also' from 
severe rickets. Cured.
39 . it 4th 2 4* * Cured.
40. n 5th ih 5 " Cured. j
41. n 20th 37 38 " Broncho - Pneumonia fflfpurringl 
in an old tuberculous 
chest. No effect.
42. n 8th 78 21 " Cured.
43. it 5th 61 10 1 Cured.
44. it 8th -ft 9 " Cured.
:
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N o. Day treat­
ment began.
1st day 
afebrile
Age Total
M&B 693
Results. 1
i
45. 3rd 8th % gms Cured.
46. n 5th l! 3 ti Cured.
47. 4th 6 th lfe 9-ir ii Cured.
48. ft 6th 1 6 ti Cured.
49. t 5 th 1 6 ii Cured.
50. rt 7 th 12 5 if Cured.
51. - 12 6
ti Marasmic child. Died on 
7th day. No effect on 
temperature.
52. 5th “7 th 23 9 " Pneumonia cured. Suffering 
also from asthma.
55. t 13th 2 30 it Cured. '
54. n 7 th 10 t Cured.
55. it 7th £ if Cured.
56. ft 12th i io£ n Badly undernourished
i a . niiT*p»6 . I
57. H 7th & 5f ft Cured.
cn 03 . 6th 8th 2 iol tt Cured.
59. t 9 th 4c 3i ft Cured.
60. 7th 8th i&- of tt
M&B 593 withheTd for 
6 days. Cured.
61. it - 50 5 ti Extreme delirium & rest­
lessness. Died 24 hours 
after admission.
62. t 8th 2 6 t M&B 693 withheld for 
3 days. Cured.
53 • 8th Toth -h y Cured.
64. 9th - ■fe 2
if Died 36 hrs.after ad­mission. Terminal Convul- |
aions.
65. t 20th 24 30 ft Unresolved pneumonia. 
Discharged well.
66. t 10th 2i 10^ it M&B 695 withheld for 6 
days. Cured.
1
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Compllcations due to Pneumonia.
The case (No.4) already quoted was the only 
patient in the series who had complications directly 
the result of the pneumonia.
For comparison I shall give the number of complicated 
cases in previous years.
1938.
In the early part of the year of 73 cases of 
pneumonia 4 patients developed empyema. All 4 were of 
pneumococcal type. Two adults were treated by rib re­
section, one adult by aspiration and the fourth case, a 
child, was treated by insertion of a cannula. All four 
were cured.
1957.
Of 84 cases, 5 developed empyema.
1. Man, aged 64 years. Pneumococcal empyema. Rib 
resected. Good result.
2. Boy, Aged 16 years. Pneumococcal empyema. Rib 
resected. Died of septicaemia later.
3. Man, aged 30 years. Streptococcal empyema. Rib 
resected. Cured.
4. Man, aged 26 years. Streptococcal empyema. Cured 
with aspiration and sulphanilamide.
5. Child, 15 months. Staphlococcal empyema. Drained 
with cannula. Cured.
1936.
Of 87 cases of pneumonia one child developed empyema. 
This was of pneumococcal type and was cured by drainage 
with a cannula.
It is my opinion that patients suffering from 
pneumonia and treated with M.&B.693 will run grave 
risk of empyema developing if they are allowed out of 
bed before the 10th day of illness.
Though in the majority of cases of both types of 
pneumonia a beneficial effect was observed, there were 
cases both of lobar and broncho-pneumonia which were 
apparently unaffected by pne drug or only temporarily 
improved. Cases Nos.20, 23, 28, 41, 56 and 65 illustrate 
that the drug is not invariably successful. In cases 20 
and 23 the dose may have been insufficient. Both occurred 
early in the series before the routine dosage was 
stabilised.
Case No.28 was a chronic bronchitis. His temperature 
fell on the 6th day, rose again on the 8th day and re­
mained elevated till the 16th day in spite of continuous 
administration of M.& B.693, and in spite of the fact that 
there was no clinical evidence of pus collecting in the 
chest. The ultimate improvement was by lysis.
Case No.41 had a broncho-pneumonia superimposed 
on a previously tuberculous chest. The drug had apparently 
no effect.
Case No.56 was a poorly nourished infant.
Case No.65 admitted on the 9th day had apparently 
an unresolved pneumonia. The M.&B.693 had no effect in 
reducing the fever,which subsided by lysis on the 20th 
day, 11 days after admission.
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There is no doubt that further bacteriological 
investigation is necessary and this may reveal that 
certain types of infecting organisms are resistant 
to the bacteriocidal effects of M.&B 69b.
Another explanation of the resistant cases is 
suggested by my experience with sulohanilamide in 
erysipelas. It may be that the drug cannot reach 
the infecting organisms in sufficient concentration, 
rtien the infected area becomes partially walled off 
from the blood or tissue fluids, as might well happen 
in collections of pus in the chest, empyema, lung abscess 
or in fibroswd areas of the lung as in a tuberculous 
lung or an unresolved pneumonia.
A case which is noc included in the above series 
and which is still in hospital may lend support to this 
theory.
A boy of 14 years, thin and nervous, with a 
previous history of bronchiectasis was admitted to 
hospital on the 2nd day of his illness. He was acutely 
ill and had all the signs and symptoms of pneumonia 
at the right base. He was given 1 gm. of M.&B.69b 
followed by \ gm. four hourly. He improved and his 
temperature fell to normal on the fourth uay of his 
illness. On the fifth day the temperature rose again 
and although hw was not now acutely ill he remained 
fevered in spite of continuous M.& B.69b administration. 
By the 11th day there was a localised patch of dullness
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about 3" in diameter in the post - axillary line at 
the right base.
The chest was explored in this region and 10 ounces
of thin purulent,ffletid pus was withdrawn. Aspiration
was repeated two days later and five days later a cannula
was inserted as the pus was becoming thicker.
grown
The only organism/from the pus was the pneumococcus 
and this in spite of continuous M.&B.693 administration 
for a total amount of 25 grammes.
This pneumococcus must have been either resistant 
to the drug or the drug was unable to get into contact 
with the organisms in sufficient concentration.
From my experience, I have concluded that when 
the M.&B.693 does not give a prompt response in the
treatment of pneumonia it is wise to regard the case as
either being a potentially complicated one,or having had 
the pneumonia super-imposed on some pre-existing chronic 
disease•
Toxic effects attributable to the M.&B.693 were 
remarkably rare. The precautions of giving patients 
only a light, sulphur frwe diet and avoiding saline 
cathartics, which are now part of the routine in all 
sulphonamide therapy, Douthwaite (19b9) were observed 
in all the cases of the series.
Nausea and sickness occurred in a few cases but 
never of sufficient severity to upset the patient 
seriously, or to make administration by mouth difficult.
Cyanosis occurred more frequently. This was 
regarded as evidence of overdosage or of idiosyncrasy 
of the patient to the drug and was taken as an indication 
for the dose to be reduced. In no case was the cyanosis 
accompanied by harmful effects to the patient, and if the 
pneumonic condition had not subsided it was always possible 
to continue with the drug in reduced dosage.
It is noticeable that M.&B.693 has less tendency to 
produce cyanosis than sulrhanilamide•
The cyanosis is now regarded as an excellent warning 
signal of possible over dosage with no harmful significance 
in itself.
Babies and children were found to tolerate the M.&B. 
693 very well Indeed. Elderly patients tended to show 
cyanosis early and required to be watched carefully for 
toxic symptoms.
There was no evidence of renal damage resulting from 
the M.&B.693 treatment.
It was not possible to carry out routine white blood 
cell counts or to investigate the nature of the changes 
taking place in the blood when cyanosis developed.
Prom the series of cases of pneumonia discussed,
It appears to me to be reasonable to conclude that M.&B.693 
is of great value In the treatment of pneumonia. The 
simplicity and safety with which it can be administered 
and the prompt and effective relief given to the patient
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make M.& B.693 therapy the method of choice in treating 
pneumonia of all types. There may, however, he a grave 
danger of the efficacy of the drug producing an unjustifiable 
relaxation of the vigilant supervision which is still 
necessary in every case.
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Summary and Conclusions.
1^
The results of treatment of a series of 224 cases 
of scarlet fever with sulphanilamide have been reviewed 
and compared with a concurrent series of 338 cases of 
scarlet fever treated without sulphanilamide.
There is no evidence that the sulphanilamide. had 
any beneficial effect in this disease whatever, either 
in the acute febrile stage or on the incidence of 
complications.
2 .
54 cases of Erysipelas were treated with sulph­
anilamide with successful results. The toxaemia and 
the diffuse inflammation respond quickly to the drug.
Attention is drawn to the fact that localised 
abscess formations are resistant to the effect of the 
drug.
3 cases of Streptococcal empyema are described.
In two cases treated with sulphanilamide by mouth 
aspiration was sufficient to cure the oondition.
In one case, treated with proseptasine, (benzyl sulph­
anilamide) the patient was benefited, but the pleural 
cavity required to be drained by the operation of rib 
resection.
Sulphanilamide given early will tend to lessen 
the frequency of, or, even abolish, the need for operative 
interference other than aspiration.
4.
In 40 cases of puerperal infection excellent results
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have been obtained in some cases treated with prontosil 
rubrum and also in other cases treated with sulphanilamide.
Cases of puerperal infection unaffected by large 
doses of both of those drugs have also been met with.
Bacteriological Investigation of the cases would 
probably have explained the variation in results.
Where laboratory facilities are not available the
use of the drugs in every severe case of puerperal
infection is justifiable.
5.
In 10 cases of Pyelitis due to infection with
coliform bacilli rapid relief of symptoms/-disappearance
of B.coli from urine was obtained with relatively small 
doses of sulphanilamide.
This drug does not prevent relapses but can be 
conveniently combined with alkaline treatment.
ii Sulphanilamide had no curative effect on 6 faecal 
carriers of Bacillus para-typhosus B.
7.
4 Cases of Meningococcal meningitis treated 
successfully with sulphanilamide or M.& B.693 and 
meningococcal antitoxin are recorded.
The impression was formed that the chemotherapy 
contributed to the success of the treatment.
8 .
5 cases of Gonococcal ophthalmia neonatorum
were treated with sulphanilamide with equivocal results. 
One case treated with M.& B.69a was cured dramatically.
9.
Uleron was used in the treatment of one case of 
Staphlococcal pyaemia without success.
10.
66 cases of pneumonia of various types were treated 
with M.& B.693. The mortality rate in the treated cases 
was 7.6% From 1935 to July 19o8 the mortality rate in 
pneumonia patients in the hospital was 18$ in 309 cases .
Chemotherapy with M.& B.693 is the best available 
treatment of pneumonia of all types.
The M.& B.693 is not invariaoiy successful. The 
unsuccessful cases may be due to a highly resistant 
infecting organism or to a partially encysted infected 
area, e.g. lung abscess.
The introduction of sulphonamide chemotherapy marks 
an important advance in the treatment of pneumonia, 
streptococcal diseases due to bacterial Invasion of 
the body, such as erysipelas, puerperal sepsis and 
streptococcal empyema, and probably also in the treatment 
of meningococcal meningitis and gonococcal ophthalmia.
The efficacy of the drugs by mouth simplifies 
treatment.
Toxic symptoms are relatively few. Cyanosis which 
frequently develops during treatment is an excellent 
indication for caution as regards dosage. Patients 
being treated with the drug should be under supervision. 
Ambulant treatment is contra-indicated on account of 
the vertigo, tremor and nervousness which may be 
produced by the drug.
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